Timothy N. Troy
FDA gives nod; Hylaform joins ranks of fillers
Santa Barbara, Calif. -- The U.S. Food and Drug Administration late last month granted approval for Inamed Corp.'s Hylaform (Hylan-B gel). The hyaluronic-acid-based dermal filler is indicated for injection into the deep dermis for correction of moderate-to-severe facial wrinkles and folds. The move, while expected, adds a few wrinkles of its own to the growing U.S. market for dermal fillers.
Contemplating the growing cosmetic trend
The cosmetic wave in dermatology dots our 25th anniversary issue, from article to article. Leaders in dermatology over the last quarter century feel about this change in one of two ways: They either encourage the trend because they see it as a new, exciting venue for dermatologists to expand their practices and meet the needs of an aging population known for its vanity, or they discourage it because they feel new-age dermatologists will focus on the trend to the detriment of true clinical practice.
Raptiva Off and Running
San Francisco - A study on Raptiva (efalizumab) shows patients with moderate-to-severe plaque psoriasis who received 12 weeks of treatment experienced a significant reduction in signs and symptoms, and patients who continued treatment to 24 weeks continued to benefit.
Cut to the Chase
Schaumburg, Ill. - A study from the American Academy of Dermatology published by the American Academy of Dermatologic Surgery calls for nationwide mandatory reporting of adverse incidents of office-based surgery -- a leveling of the playing field for all specialties operating in a cosmetic surgical setting.
Raptiva Rolls Out
San Francisco ?? Sources familiar with Raptiva (efalizumab) hail its approval by the U.S. Food and Drug Administration last month as nothing but an enhancement to patient compliance and successful treatment of chronic moderate-to-severe plaque psoriasis.
Communication is Key to Your Future
It's been quite a year for dermatology, and many issues face the market as it continues its forward path of improving the quality of care as well as the quality of its delivery system.
Safety Assured
Chicago - The American Academy of Dermatology Assn. wasted no time in responding to a study in Archives of Surgery that questioned the safety of procedures performed outside of ambulatory care centers.
Limited TIMs?
London -- A report published by Britain's National Prescribing Center saying that Fujisawa's Protopic (tacrolimus) and Novartis' Elidel (pimecrolimus) have only a limited role in the treatment of eczema was intended for general practitioners rather than dermatologists and refers mostly to mild cases treated in primary care settings.
Filler vs. Filler
San Diego - Legal disputes between companies regarding assumptions of patent right and licensing normally are not important to physicians using the products, but a recent action initiated by Artes Medical against competitor BioForm Inc. suggests a dispute could reach the user-level.
Losing Lindane
Washington - A spate of deaths and other significant risks prompted the U.S. Food and Drug Administration to issue a public-health advisory regarding the safety of topical formulations of Lindane shampoo and lotion products for the treatment of scabies and lice.


View Results